Evidence map›Paper›PMID 37195532›Full record

ArticleAdvances in experimental medicine and biology2023

Lung-on-a-Chip Models of the Lung Parenchyma.

Pauline Zamprogno, Jan Schulte, Dario Ferrari, Karin Rechberger, Arunima Sengupta, Lisette van Os, Tobias Weber, Soheila Zeinali, Thomas Geiser, Olivier T Guenat

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Pauline Zamprogno *Organs-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland.
Jan Schulte *Organs-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland.
Dario FerrariOrgans-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland.
Karin RechbergerOrgans-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland.
Arunima SenguptaOrgans-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland.
Lisette van OsOrgans-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland.
Tobias WeberOrgans-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland.
Soheila ZeinaliOrgans-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland.
Thomas GeiserDepartment of Pulmonary Medicine, University Hospital of Bern, Bern, Switzerland.
Olivier T GuenatOrgans-on-Chip Technologies Laboratory, ARTORG Center, University of Bern, Bern, Switzerland. olivier.guenat@unibe.ch.
University of Bern · CHUniversity Hospital of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the publication of the first lung-on-a-chip in 2010, research has made tremendous progress in mimicking the cellular environment of healthy and diseased alveoli. As the first lung-on-a-chip products have recently reached the market, innovative solutions to even better mimic the alveolar barrier are paving the way for the next generation lung-on-chips. The original polymeric membranes made of PDMS are being replaced by hydrogel membranes made of proteins from the lung extracellular matrix, whose chemical and physical properties exceed those of the original membranes. Other aspects of the alveolar environment are replicated, such as the size of the alveoli, their three-dimensional structure, and their arrangement. By tuning the properties of this environment, the phenotype of alveolar cells can be tuned, and the functions of the air-blood barrier can be reproduced, allowing complex biological processes to be mimicked. Lung-on-a-chip technologies also provide the possibility of obtaining biological information that was not possible with conventional in vitro systems. Pulmonary edema leaking through a damaged alveolar barrier and barrier stiffening due to excessive accumulation of extracellular matrix proteins can now be reproduced. Provided that the challenges of this young technology are overcome, there is no doubt that many application areas will benefit greatly.

Indexed as

LungPulmonary AlveoliExtracellular MatrixLab-On-A-Chip DevicesAlveolar cellsAlveolar microenvironmentCOVIDLung diseasesLung in-vitro modelMicrofluidicsOrgans-on-chip

Identifiers

PMID37195532
OpenAlexW4376871942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.